Read the actual FDA label for the medications used in gender-affirming care. None of them are approved for it, all of them are prescribed for it, and knowing exactly what the label says before an insurer quotes it at you is worth twenty minutes.
Applies to Denials of hormones or blockers as experimental, unproven, or not medically necessary.
Testosterone is approved for testosterone deficiency. Spironolactone is approved for heart failure. Leuprolide is approved for advanced prostate cancer. None of the medications used in gender-affirming care are FDA-approved for gender-affirming care, and all of them are prescribed for it every day.
That gap has a name and it is not a scandal. Prescribing a drug for something not on its label is off-label use. A label records what a manufacturer applied for and paid to prove; it is a marketing authorization, not a list of the only permitted uses. A great deal of ordinary medicine happens off-label.
An insurer may still point at it. Some denials quote the label to argue the use is unproven. If that is coming, it is better to have read the label yourself than to meet it for the first time in the letter — and the answer to it is never the label. It is the published research and your clinician’s judgment, and there is a research search on this site for that.
One indication on these labels is worth more than the rest. If puberty blockers are denied as experimental, the answer is that this drug class holds an FDA-approved indication for suppressing puberty in children. Read directly from the labels: Lupron Depot-PED (leuprolide) is “indicated for the treatment of pediatric patients with central precocious puberty”, and SUPPRELIN LA (histrelin) and TRIPTODUR (triptorelin) carry the same indication. That is not approval for gender-affirming care. It is approval for suppressing puberty, in children, with an established record in that population — so a plan calling the mechanism experimental is calling an approved indication experimental.
The same argument exists for estrogen, and it reaches far more people. The ORAL ESTRADIOL TABLET label carries an approved indication for “treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure” — read directly from the label this page returns. That is a much closer description of the clinical situation in feminizing therapy than the menopause indications above it. Check it against the specific product you are prescribed: the vaginal cream label does NOT carry that line, so the argument belongs to the tablets.
Read your plan’s own definition before you reach for the research. Most plan documents define experimental or investigational with a carve-out for uses supported by standard drug compendia or by peer-reviewed literature. If yours has one, that is a plan-document argument and it comes first: find the definition, find the exception, show the use falls inside it. It is the same sequence the wrong-standard page teaches. We have not verified how any particular plan words that carve-out, so treat it as something to look for rather than something to assume.
Labels come from the FDA’s own database, through this site’s server. Choosing a medication tells this server which one; it is not recorded.
None of these labels will mention gender-affirming care. That is expected.
A label says what a manufacturer asked the FDA to approve and paid to prove. Prescribing a drug for something not on its label is called off-label use, and it is how a great deal of ordinary medicine is practiced — the label is a marketing authorization, not a list of the only permitted uses. A plan may still point at the label and call the use unproven, so it is worth knowing exactly what it says before they quote it at you.
A-S Medication Solutions · VAGINAL
INDICATIONS AND USAGE Estradiol Vaginal Cream, 0.01% is indicated in the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause.
Direct_Rx · ORAL
Estradiol tablets are indicated in the: 1. Treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 3. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. 4. Treatment of breast cancer (for palliation
What to do with this. Two of these labels carry an approved indication that answers an experimental denial directly: the puberty blockers, and oral estradiol tablets for hypoestrogenism. For everything else the label will not help you, because the use is off-label and the label only ever describes what a manufacturer applied for. There the answer is your plan’s own definition of experimental, then the published evidence and your clinician’s judgment. This page is here so the label does not surprise you, and there is a research search on this site for the other half.
Last updated 2026-08-09 · Not legal or medical advice
